Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Chronic Lymphocytic Leukemia: Ibrutinib, Idelalisib, and Venetoclax.

about

Efficacy and safety of B-cell receptor signaling pathway inhibitors in relapsed/refractory chronic lymphocytic leukemia: a systematic review and meta-analysis of randomized clinical trials.

P2860

Q50166015-72983A86-51AF-4EBA-8284-C1D168488C06

P2860

Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Chronic Lymphocytic Leukemia: Ibrutinib, Idelalisib, and Venetoclax.

Item

http://www.wikidata.org/entity/Q39200835

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Pharmacokinetic and Pharmacody ...... b, Idelalisib, and Venetoclax.

@en

Pharmacokinetic and Pharmacody ...... b, Idelalisib, and Venetoclax.

@nl

type

Item

label

Pharmacokinetic and Pharmacody ...... b, Idelalisib, and Venetoclax.

@en

Pharmacokinetic and Pharmacody ...... b, Idelalisib, and Venetoclax.

@nl

prefLabel

Pharmacokinetic and Pharmacody ...... b, Idelalisib, and Venetoclax.

@en

Pharmacokinetic and Pharmacody ...... b, Idelalisib, and Venetoclax.

@nl

P1476

Pharmacokinetic and Pharmacody ...... b, Idelalisib, and Venetoclax.

@en

P2093

Allison Winter

http://www.w3.org/2001/XMLSchema#string

Brian T Hill

http://www.w3.org/2001/XMLSchema#string

P2860

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study

Idelalisib and rituximab in relapsed chronic lymphocytic leukemia

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia

Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease.

Idelalisib: A Novel PI3Kδ Inhibitor for Chronic Lymphocytic Leukemia.

Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.

Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study.

PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma.

Ibrutinib inhibits BCR and NF-κB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL

P2888

s40262-017-0529-1

P304

1255-1266

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40262-017-0529-1

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Madeline Waldron

P577

2017-03-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28343293

http://www.w3.org/2001/XMLSchema#string

P921

lymphocyte

Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Chronic Lymphocytic Leukemia: Ibrutinib, Idelalisib, and Venetoclax.

about

P2860

P2860

Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Chronic Lymphocytic Leukemia: Ibrutinib, Idelalisib, and Venetoclax.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P921